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 ABSTRACT 
Nowadays, colorectal cancer is the third most common cancer worldwide. There 
are some therapies to treat this cancer, such as radiotherapy and chemotherapy. 
However, their efficacy can be decreased or completely inhibited by one 
characteristic of the tumor cells, hypoxia. Recently, has appeared one alternative 
therapy for those patients with inoperable colon cancer and it uses light sources 
to induce cell death by the production of singlet oxygen and other species of 
ROS. This therapy is called photodynamic therapy (PDT) but its effectiveness can 
be affected too by the hypoxic tumor cells. To increase the efficacy of PDT 
treatment it has been used the hyperbaric oxygen therapy (HBOT), which 
overcomes the hypoxic state of cancer cells. The combined therapies have been 
applied using different conditions and their effect has been analyzed by MTT 
assay and cell cycle and cellular viability analysis by cytometry. The obtained 
results revealed that combination of PDT and HBOT is promising and that results 
of combination of PDT followed by HBOT during 60 minutes should be further 
studied.
-11- 
RESUMEN  
El tercer cáncer más común hoy en día es el cáncer colorrectal. Existen varios 
tratamientos para eliminarlo, como la radioterapia y quimioterapia. La eficacia de 
las terapias anticancerígenas puede ser disminuida o anulada por una 
característica de las células tumorales, la hipoxia. Ha surgido recientemente una 
terapia alternativa para pacientes con cáncer colorrectal que no puede ser 
operado y que utiliza fuentes de luz para eliminar los tejidos cancerosos 
mediante la producción de oxígeno singlete y otras especies de ERO. Esta terapia 
se llama terapia fotodinámica (TF) pero su efectividad también puede verse 
afectada por las células tumorales hipóxicas. Para mejorar la eficacia de la TF en 
el tratamiento de cáncer de colon se ha utilizado la terapia de oxígeno 
hiperbárico (TOHB), que elimina el estado de hipoxia celular. La combinación de 
las terapias ha sido aplicada usando diversas condiciones y su efecto se ha 
analizado mediante los ensayos de MTT y el análisis de ciclo celular y viabilidad 
celular por citometría. Los resultados obtenidos dan una visión esperanzadora de 
la combinación de TF con TOHB y  en análisis futuros, deberán ser corroborados 
los resultados de la terapia de TF seguida de TOHB durante 60 minutos. 
-12- 
RESUM  
El tercer càncer més comú avui dia és el càrcer colorectal. Existeixen diverses 
teràpies per combatre’l com la radioteràpia i la quimioteràpia. L’eficàcia de les 
teràpies anticancerígenes es pot veure disminuïda o anul·lada per una 
característica de les cèl·lules cancerígenes, la hipòxia. Ha sorgit recentment una 
teràpia alternativa per als pacients amb càncer de colon que no pot ser operat. 
Aquesta utilitza fonts de llum per eliminar el teixit cancerós mitjançant la 
producció d’oxigen singlet i altres espècies de ERO, s’anomena teràpia 
fotodinàmica (TF). No obstant, la seva efectivitat també es pot veure afectada 
per les cèl·lules tumorals hipòxiques. Per millorar la seva eficàcia en el 
tractament del càncer colorectal s’ha utilitzat la teràpia d’oxigen hiperbàric 
(TOHB), que elimina l’estat d’hipòxia cel·lular. La combinació de les teràpies ha 
sigut aplicada utilitzant diverses condicions i el seu efecte s’ha analitzat 
mitjançant l’assaig MTT i l’anàlisi de cicle cel·lular i de viabilitat cel·lular per 
citometria. Els resultats obtinguts donen una visió esperançadora de la 
combinació de TF i TOHB i en anàlisis futurs, s’haurà de corroborar els resultats 
de la teràpia de TF seguida de TOHB durant 60 minuts.  
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CHAPTER 1: 
OBJECTIVE 
The main purpose of the present project is to evaluate the combination of 
hyperbaric oxygen therapy (HBOT) and photodynamic therapy (PDT) in colorectal 
adenocarcinoma cell line as a new alternative therapy to treat this cancer. In 
vitro studies have been performed to verify the therapeutic outcome produced by 
the combination of both therapies in different conditions. 
Cells were incubated with the photosensitizer (PS) 5,15-bis(2-bromo-3-
hydroxyphenyl) chlorin (BBr2HPC) to perform PDT by irradiation. To create 
conditions of increased oxygen partial pressure a prototype has been used in 
order to summit the cells to HBOT conditions. After summiting the cells to 
corresponding therapies, the effect on metabolic activity (MTT), viability and 
types of cell death (annexin V and propidium iodine double labeling by flow 
cytometry) and the alterations in the cell cycle (propidium iodine by flow 
cytometry) were evaluated.  
Therapies applied consisted in perform PDT based on BBr2HPC by incubating 
cells with different concentrations of PS and by irradiating with a total energy of 
10J. HBOT can be applied immediately before or after PDT, by a period of 30min 
or 60min. Evaluation of metabolic activity is performed both 24h and 48h after 
therapies. To evaluate cell viability and cell cycle alterations we studied the 
therapy performed with the EC50 value previously determined to BBr2HPC 
(Laranjo 2014) combined with HBOT during 60min, after PDT. 
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CHAPTER 2: 
INTRODUCTION 
The aim of this chapter is to expose all the theoretical foundations needed for the 
complete understanding of the present project. In the course of this chapter it is 
going to be explained the kind of cancer studied, its main cell characteristic and 
the therapies applied to treat this cancer cell line.  
 
2.1 Colorectal adenocarcinoma  
Cancer is one of the main mortality causes all over the world with 8,2 millions of 
deaths and 14 millions of new diagnosis in 2012. (World Health Organization, 
WHO; U.S National Library of Medicine) Cancer cell alters its metabolism in 
response to a challenging environment by promoting cell growth and 
proliferation, diverging significantly from normal tissues. (Abrantes et al. 2014) 
Increased rate of multiplication of abnormal cells makes possible their extension 
to different parts of the body, this process is known as metastasis. Metastasis is 
the main cause of dead by cancer. One of the cancers more diagnosed between 
men and women is colorectal cancer. (WHO; U.S National Library of Medicine) 
Colorectal cancer is formed in the tissues of the colon or in the tissues of the 
rectum, both in the large intestine. Most colorectal cancers are adenocarcinomas, 
cancers that begin in cells that make and release mucus and other 
fluids. (National Cancer Institute, NCI) 
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General information about colorectal 
cancer can be found in the next 
sections. 
 
2.1.1 Epidemiology 
Worldwide, colorectal cancer is the 
third most common form of cancer. 
(International Agency for Research on 
Cancer, IARC) Colorectal cancer 
occurs when tumors form in the lining 
of the large intestine formed by colon, 
rectum and anus as it is shown in 
Figure 1. Colorectal cancer usually 
develops from a polyp, a benign 
tumor found in the walls of the colon 
or rectum. Its development is slow 
and it can take few years to turn into cancer if undetected or ignored. The type 
of polyp with biggest risk to become cancerous is adenoma. (American Society 
for Gastrointestinal Endoscopy, ASGE; U.S National Library of Medicine) 
The risk of developing colon cancer can depend on hereditary factors, which are 
the high-risk group, and the non-hereditary factors, that can reduce its 
probability by having a healthy lifestyle. Limiting screening or early cancer 
detection to only high-risk groups would miss the majority of colorectal cancers. 
(NCI; U.S National Library of Medicine) The factors that increase the risk of rectal 
cancer include the following: (ASGE; Burkitt 1993; NCI; U.S National Library of 
Medicine) 
 
 Hereditary factors: hereditary nonpolyposis colorectal cancer, hereditary 
polyposis disorders, hamartomatous disorders, personal or first-degree 
relative (parent, sibling or offspring) history of colorectal cancer or 
colorectal adenomas and personal history of ovarian, endometrial or 
breast cancer. 
 
Figure 1. Lower gastrointestinal 
anatomy. (NCI) 
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 Non-Hereditary factors: upper age than 50, a diet high in fat and 
obesity, smoke and medium or high consumption of alcohol and sedentary 
lifestyle. 
 
It is a highly treatable and often curable disease when localized to the bowel. 
Surgery is the primary form of treatment and results in cure in approximately 
50% of the patients. Recurrence following surgery is a major problem and is 
often the ultimate cause of death. (U.S National Library of Medicine) 
About 54% of colorectal cancer cases occurred in the most developed countries, 
being the highest incidence of colorectal cancer in Oceania and Europe and the 
lowest incidence in Africa and Asia. In Figure 2 it is shown the estimated 
incidence and mortality worldwide for the year 2012. (IARC) 
 
 
Figure 2. Estimated incidence and mortality worldwide of colon cancer in 2012. 
(adapted from IARC) 
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2.1.2 Classification, clinical presentation and diagnosis 
The American Joint Committee on Cancer (AJCC) has designated the TNM1 
classification to define colorectal cancer. It consists in 4 stages defined by the 
growth of the primary tumor (T), the propagation to the regional lymph nodes 
(N) and the propagation to other organs or distant metastasis (M). 
Stage 1 colorectal adenocarcinomas are small and confined to the colon and 
stage 4 tumors have spread beyond areas near the colon and other parts of the 
body. Stages between 2 and 3 describe conditions in between these two 
extremes. In Figure 3 is represented this progression. 
Colon adenocarcinoma progresses slowly and may not present symptoms for up 
to five years. As the cancer grows, symptoms become more likely and can 
include rectal bleeding, fatigue, shortness of breath, angina and changes in 
bowel habits, abdominal discomfort and anemia or bowel obstruction. Diarrhea, 
constipation, weight loss with no known reason, nausea and vomiting are also 
symptoms described. (NCI) 
 
 
(a) 
 
(b) 
                                                             
1 The TNM classification can be found in the National Cancer Institute website, which is the following: 
http://www.cancer.gov/cancertopics/pdq/treatment/rectal/HealthProfessional/page4/page3.  
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(c) 
 
(d) 
Figure 3. Stage of colorectal cancer progression. (a) Stage I: the cancer is found in the 
mucosa, submucosa and muscle layers. (b) Stage II: it spreads through the serosa and 
can reach nearby organs. (c) Stage III: cancer reaches the lymph nodes and nearby 
organs. (d)  Stage IV: cancer spreads through the blood and lymph nodes to other parts 
of the body. (adapted from NCI) 
 
Because most colon adenocarcinomas do not present symptoms it is important to 
have screening tests, especially those population over 50. About 5 to 10 percent 
of colon cancers are initially discovered during a digital rectal exam, where 
abnormal areas are searched. Also, the presence of blood in the stool can be a 
sign for cancer or polyp. (American Cancer Society, ACS; NCI) 
The tests and examinations used for colorectal cancer detection include: 
 
 Blood test: it can be a complete blood count to find possible anemia or it 
can check liver enzymes for a possible propagation of the cancer to the 
liver and tumor markers.  
 Colonoscopy: endoscopic examination of the entire colon and rectum. It 
provides a visual diagnosis and special instruments can be passed through 
the colonoscope to biopsy or remove any suspicious-looking areas such as 
polyps, if needed. 
 Sigmoidoscopy: is like a colonoscopy but just examining the last part of 
the colon. 
 Double-contrast barium enema: X-ray scan of the colon and rectum. 
Olga Ciutad Castejón 
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In some situations imaging techniques may be ordered to check if the tumor has 
spread to other organs or parts of the body and especially to the lungs, lymph 
nodes, liver or ovaries. Those include: computed tomography (CT), 
ultrasonography (US), magnetic resonance imaging (MRI), X-ray, angiography 
and positron emission tomography (PET) scan. (ACS and NCI) 
 
2.1.3 Treatment 
Depending on the stage of the cancer, two or more types of treatment may be 
combined at the same time or used before or after another. The main types of 
treatment that can be used for colon and rectal cancer are: 
 
 Surgery: can usually cure it when it is found early. Is generally 
recommended for 90 percent of patients. 
 Radiation therapy: can be used to shrink tumors or to destroy cancer 
cells that remain after surgery. 
 Chemotherapy: recommended if the cancer has spread. Can be used 
before and after surgery and can be combined with immunotherapy or 
radiation therapy. 
 Ablation or embolization: destroy tumors without removing them or try 
to block or reduce the blood flow to cancer cells by injecting substances. 
Used for advanced cancer or when it has spread to the liver or other parts. 
 
Other factors to consider as well as the stage of the cancer include the overall 
health, the likely side effects of the treatment, and the probability of curing the 
disease, extending life or relieving symptoms. (ACS; NCI) 
Photodynamic therapy (PDT) is a relatively new alternative modality for 
patients with colorectal cancers unsuitable for operation. The important biological 
advantages of PDT are that the risk of perforation is small even if full thickness 
necrosis is produced to eradicate the tumor and the areas of necrosis heal 
predominantly by regeneration with little scarring. The major disadvantage of 
PDT is that the amount of tumor destruction is limited by the penetration of light. 
(Barr et al. 1990) 
Photodynamic therapy improvement with hyperbaric oxygen therapy for human colon cancer treatment 
-22- 
2.2 Hypoxia in cancer cells 
Hypoxia is a common characteristic of tumoral cells, becoming a key factor for 
tumor progression and resistance to anticancer therapy. The hypoxic tissue areas 
have O2 tensions (pO2 values) lower than 2,5mmHg. Hypoxic areas arise as a 
result of an imbalance between the supply and consumption of oxygen, being the 
result of an imbalance between tissue growth and the development of new 
vasculature. Areas with a poorer oxygenation than their respective normal 
tissues have been found in cancers of the vulva, prostate, rectum, pancreas, 
lung, brain tumors, soft tissue sarcomas, non-Hodgkin’s lymphomas, malignant 
melanomas, metastatic liver tumors, renal cell cancer and breast, uterine cervix 
and head and neck cancer. Hypoxic areas are also independent of clinical size, 
stage, histology, grade, nodal status or patient demographics. Local tumor 
recurrences have a higher hypoxic fraction than the respective primary tumors. 
(Abrantes et al. 2014; Daruwalla and Christophi 2006; Vaupel and Mayer 2007) 
The growth of tumors is limited by the delivery of oxygen, nutrients and the 
removal of waste products. As a tumor grows, cells undergo nutrient deprivation 
and acidosis and they become hypoxic making its microenvironment toxic. Tumor 
cells can adapt to the ischemic and low nutrient microenvironment by three main 
adaptations: forming an aberrant vascular network, evading apoptotic 
destruction and switching to anaerobic glycolysis. All three mechanisms are 
driven by the hypoxic tumor adverse microenvironment and make tumor cells 
survive. (Abrantes et al. 2014; Daruwalla and Christophi 2006) 
Hypoxia regulates many pathways including angiogenesis, glycolysis, metastasis, 
apoptosis and pH regulation, among others, by affecting the expression of many 
gene products that are involved in the pathways mentioned. (Daruwalla and 
Christophi 2006) 
Hypoxia has been suggested as an adverse prognostic factor for patient 
outcome. There is an unfavorable therapeutic response and a worse disease-free 
survival for patients with hypoxic cancers or soft tissue sarcomas. Regions of 
hypoxia of tumors are associated with slowly proliferating cells. Those cells are 
mostly resistant to chemotherapy due to rapidly dividing cells targets of the 
standard chemotherapy but it has also been shown to diminish the efficacy of 
certain regimens of radiotherapy, photodynamic therapy and immunotherapy. 
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The degree of inhibition depends on the severity and duration of hypoxia. 
(Sudhakar et al. 2013; Vaupel and Mayer 2007) 
 
2.3 Hyperbaric oxygen therapy (HBOT) 
One unique feature of tumors is the presence of hypoxic regions, which occur 
predominantly at the tumor inner part. Hypoxia has a major impact on various 
aspects of tumor cell function and proliferation. Hypoxic tumor cells are relatively 
insensitive to conventional therapy due to cellular adaptations caused by the 
hypoxic microenvironment. To alter the hypoxic state and to reverse these 
adaptations and improve treatment outcome, one way to increase tumor oxygen 
tensions is by hyperbaric oxygen therapy (HBOT). (Daruwalla and Christophi 
2006; Ogawa et al. 2013) 
 
2.3.1 What is it? 
HBOT is defined by the Undersea and Hyperbaric Medical Society (UHMS) as a 
treatment in which a patient intermittently breathes 100% oxygen while the 
treatment chamber is pressurized to a pressure greater than sea level (1atm). 
The pressure increase must be systemic and may be applied in monoplace 
(single person) or multiplace chambers. 
Physiologically, short-term effects of hyperbaric oxygen (HBO) include 
vasoconstriction compensated by increased plasma oxygen carriage, enhanced 
oxygen delivery to ischemic tissues, reduction of edema, phagocytosis activation 
and an anti-inflammatory effect, enabling normal host responses to infection and 
ischaemia. Long-term effects of HBO include neovascularization, osteogenesis 
and the stimulation of collagen formation by fibroblasts. (Atrick et al. 1996; 
Daruwalla and Christophi 2006; Gill and Bell 2004; Ogawa et al. 2013) 
Hyperoxia as a result of HBOT also induce the formation of reactive oxygen 
species (ROS) or free radicals, which can damage tumors by inducing excessive 
oxidative stress. In nonmalignant cells, ROS levels are relatively low and 
regulated and play a duel role in tumor growth. Initially, at low levels, ROS aid 
tumor progression via DNA damage and uncontrolled proliferation of a 
genomically unstable and highly aggressive cell line. In excess however, ROS 
become toxic to tumor cells inducing to a programmed cellular death, named 
Photodynamic therapy improvement with hyperbaric oxygen therapy for human colon cancer treatment 
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apoptosis. The most damaging active oxygen species are superoxide anion (O2·), 
hydroxyl radical (OH·), hydrogen peroxide (H2O2) and singlet oxygen (
1O2). 
The effect of HBOT is dependent on the tumor’s type and stage and the HBOT 
regimen, timing, duration, atmospheric pressure and number of HBO exposures. 
Although most of the experimental and clinical studies suggest that HBOT has no 
direct effect on tumors growth and remains ineffective as a stand-alone therapy, 
may enhance the efficacy of certain therapies that are limited due to the hypoxic 
tumor microenvironment when used in an adjuvant setting with certain types of 
malignancy. (Daruwalla and Christophi 2006) 
Some treatments used in combination with HBOT to treat malignant tumors are 
radiotherapy, chemotherapy and photodynamic therapy. The use of HBOT as an 
adjuvant treatment is justified by the following: (Daruwalla and Christophi 2006; 
Ogawa et al. 2013) 
 
 Improved oxygenation improves drug delivery to hypoxic regions in the 
tumor.  
 Remove the hypoxic stimulus that drives angiogenesis and may also cause 
cells to enter a proliferative stage, thus sensitizing them to others 
therapies. 
 Increasing intratumoral ROS levels beyond the threshold may induce 
tumor destruction. 
 
2.3.2 Therapeutic uses 
In general, high-grade gliomas, advanced head and neck cancers and advanced 
uterine cervical cancers in particular have large numbers of hypoxic cells that 
exhibit poor responses to therapy. (Ogawa et al. 2013) Clinically, HBO has been 
investigated as an adjuvant therapy when combined with radiotherapy, 
chemotherapy and photodynamic therapy to treat malignant tumors: (Daruwalla 
and Christophi 2006) 
 
 Radiotherapy induces DNA damage through the ionization of oxygen to 
produce ROS. Several studies have reported that radiotherapy 
immediately after HBOT was safe and seemed to be effective in patients 
Olga Ciutad Castejón 
-25- 
with high-grade gliomas. Moreover, the addition of HBO may protect 
normal tissues from radiation injury. (Ogawa et al. 2013) 
 HBO may help overcome chemotherapy resistance in hypoxic tumors by 
increasing tumor perfusion and cellular sensitivity. HBOT in combination 
with chemotherapy increases cellular uptake of certain anticancer drugs 
and the susceptibility of cells to these drugs. 
 The response to photodynamic therapy depends on adequate tumor 
oxygenation as well as sufficient intratumoral accumulation of the 
photosensitizing agent so HBO may improve the effects of PDT by 
improving tumor perfusion and increasing ROS production, specifically the 
amount of singlet oxygen. 
 
In hypoxic conditions, HBO reduces infection and cell-death and maintains tissue 
viability while healing occurs. HBOT is widely accepted as the only treatment for 
the conditions found on the UHMS lists in Table 1 for which research data and 
extensive positive clinical experience, with a varying evidence base, have 
become recommended and used for a wide range of medical conditions. (Atrick 
et al. 1996 and Gill and Bell 2004) 
 
Table 1. UHMS approved indications for hyperbaric oxygen therapy, diseases for which 
HBOT is currently used. (adapted from Atrick et al. 1996, Gill and Bell 2004; Ogawa et al. 
2013) 
 Arterial gas embolism, 
 Carbon monoxide poisoning; cyanide poisoning; smoke inhalation, 
 Clostridial myostitis and myonecrosis (gas gangrene), 
 Crush injuries, compartment syndromes and other acute traumatic 
ischemic injury, 
 Decompression sickness (DCS), 
 Problem wounds,  
 Anemia due to exceptional blood loss, 
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 Intracranial abscess, 
 Necrotizing soft tissue infections (necrotizing fasciitis), 
 Refractory osteomyelitis, 
 Compromised skin grafts and flap, 
 Delayed radiation-induced tissue injury (LRTI), 
 Thermal burns. 
 
HBOT has been proposed for other conditions, shown in Table 2, that have been 
not approved by the UHMS yet. 
 
Table 2. Other suggested indications for HBOT. (adapted from Gill and Bell 2004) 
 Acute cerebrovascular 
incidents, 
• Spinal cord injury, 
 Cerebral oedema, 
 Intra-abdominal abscess, 
 Head injury, 
 Acute central retinal artery 
insufficiency, 
 Meningitis, 
 Brown recluse spider bite, 
 Ischaemia-reperfusion 
injury, 
 Sickle cell crisis, 
 Lepromatous leprosy, 
 Fracture healing and bone grafting, 
 Pseudomonas colitis, 
 Hydrogen sulphate or carbon 
tetrachloride poisoning. 
 
2.3.3 How is it used? 
To be effective, HBO must be inhaled in the atmosphere or administrated 
through an endotracheal tube in monoplace chambers or through masks, tight-
fitting hoods or endotracheal tubes in multiplace chambers. Their portability, 
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minimal personnel requirements and relatively low cost have made monoplace 
chambers the most common type of chamber worldwide. (Atrick et al. 1996; Gill 
and Bell 2004) It can also be found mobile multiplace chambers and portable 
monoplace chambers. That equipment is shown in Figure 4. 
 
 
(a) 
 
(b) 
 
(c) 
 
(d) 
Figure 4. Types of hyperbaric chambers (a) Standard monoplace chamber (Sigma36, 
Perry Baromedical) (b) Portable monoplace chamber (Solace210, OxyHealth) (c) 
Standard multiplace chamber (HAUX-STARMED 2200, HAUX Life Support) (d) Mobile 
multiplace chamber (OxyHeal 4000-T, OxyHeal Health Group). 
 
The duration of single treatments varies from 45 minutes for carbon monoxide 
poisoning to several hours for some severe decompression disorders and for 
treatment of wounds that do not respond to debridement or antibiotics most 
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protocols average 90 minutes for each of 20 to 30 treatments. (Atrick et al. 
1996) 
HBO when applied as an adjuvant therapy can be administered simultaneously, 
previous to irradiation to increase the oxygen tension of hypoxic tumor cells or 
after irradiation to reduce radiation-induced tissue injury. However, the 
administration of HBO inside a pressure chamber while patients are irradiated is 
difficult and costly; a limited number of hyperbaric facilities are located in the 
proximity of radiation oncology departments. (Daruwalla and Christophi 2006) 
 
2.3.4 Adverse effects and contraindications 
HBO treatment is a relatively safe treatment but carries some risks due to the 
increased pressure and hyperoxia. According to standard protocols, with oxygen 
pressures not exceeding 3atm and treatment sessions limited to a maximum of 
120 minutes HBOT is safe, however, some adverse effects may occur. 
The most common side effect of oxygen toxicity is a progressive and reversible 
myopia, thought to be due to physical lens deformation consequence of the 
direct toxic effect. A few patients may experience pain from different 
barotraumas as a result of rapid pressure changes. The most common are middle 
ear and cranial sinuses barotraumas but others extremely rare can occur like 
pulmonary, pneumothorax, inner ear or dental barotraumas. 
Psychological side effects such as claustrophobia are common and can be a 
problem in monoplace chambers. Accidents are a risk due to the enriched oxygen 
and inaccessibility. (Atrick et al. 1996; Gill and Bell 2004) 
The only absolute contraindication to HBOT is an untreated tension 
pneumothorax and this must be excluded before treatment. Relative 
contraindications include impaired pressure equalization and cardiac disease. 
(Gill and Bell 2004) 
 
2.3.5 Future perspectives 
The discovery of beneficial cellular and biochemical effects has strengthened the 
rationale for administering hyperbaric oxygen as therapy in patients with some of 
the diseases mentioned in Table 1. (Atrick et al. 1996) 
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To date, experimental and clinical evidences of the HBOT effect combined with 
therapies are limited. The lack of effect of HBO in experimental models as a 
stand-alone therapy may explain why it has not been investigated extensively in 
a clinical setting. Nevertheless, by altering oxygen levels in vivo, HBO can 
improve the radiosensitivity of tumors, enhance photodynamic therapy or 
enhance oxidative stress and tumor cell kill of certain chemotherapy. The 
limitations of HBOT include the placing of patients in HBO chambers while 
simultaneously administered with a cancer therapy. (Daruwalla and Christophi 
2006) 
HBOT is expensive, not universally available and not without risks; further 
research is needed to establish its efficacy and safety in other conditions. 
Consideration should be given as to the cost involved in such combined therapy 
against the extent of benefit that can be achieved. (Daruwalla and Christophi 
2006; Gill and Bell 2004) 
 
2.4 Photodynamic therapy (PDT) 
PDT is increasingly being recognized as an alternative treatment modality for 
solid cancers, like carcinomas, and is able to induce cell death by oxidative stress 
trough activation with light of a non-toxic photosensitizer. (Teixo 2013; 
Triesscheijn et al. 2006) 
 
2.4.1 What is it? 
PDT involves two relatively simple procedures: the administration of a 
photosensitizer (PS) followed by local illumination of the tumor with light of the 
appropriate wavelength to activate the specific drug. Light can then be targeted 
to the tumor site. Photochemical activation of the photosensitizing agent 
generates highly toxic singlet oxygen and other ROS, which can cause 
intracellular death. (Daruwalla and Christophi 2006; Triesscheijn et al. 2006) 
Activation of the photosensitizer upon absorption of the light transforms the PS 
from its ground state (1PS) into an excited singlet state (1PS*). From this state 
PS may decay directly back to ground state by emitting fluorescence, used 
clinically for photodetection. However, to obtain a therapeutic photodynamic 
effect, the photosensitizer must undergo electron spin conversion to its triplet 
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state (3PS*). This process is shown in Figure 5. Two possible reactions can 
occur: (Triesscheijn et al. 2006) 
 
 Type I: In the presence of oxygen, the excited molecule can react directly 
with a substrate, by proton or electron transfer, to form radicals or radical 
ions, which can interact with oxygen to produce oxygenated products. 
 Type II: The energy of the excited photosensitizer can be directly 
transferred to oxygen to form singlet oxygen, which is the most damaging 
species generated during PDT. 
 
Singlet oxygen generated by the photochemical reaction can directly induce 
tumor cell deaths by the induction of apoptosis and necrosis. In addition to 
directly elimination of cancer cells, PDT appears to shrink or destroy tumors in 
two other ways: it can damage the blood vessels of the tumor and surrounding 
healthy vessels, resulting in indirect tumor kill via the induction of hypoxia and 
starvation, and also is able to initiate an immune response against the remaining 
tumor cells. (NCI; Triesscheijn et al. 2006) 
There are tumor tissue properties that made tumor cells internalize more PS than 
the normal tissue such as their lower pH and a higher expression of low density 
lipoproteins receptors. Together with a local illumination of the tumor by the light 
source make PDT a high selective therapy able to reduce the risks of damaging 
normal cells with other therapies like radio and chemotherapy. (Teixo 2013) 
 
Figure 5. Principle of PDT. After light activation, the PS transforms into its excited 
triple state, enabling two possible reactions: type I form radicals and type II singlet 
oxygen. (Triesscheijn et al. 2006) 
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The efficacy of PDT in the treatment of cancer depends on the type of 
photosensitizer, drug concentration and intracellular localization, light dose 
(fluence), dose rate (fluence rate) and oxygen availability. (NCI; Triesscheijn et 
al. 2006) 
 
2.4.2 Therapeutic uses 
To date, exist a few approved PS for treat some kind of cancers. Those cancers 
are: bladder cancer, skin cancer, head and neck cancer, esophageal cancer, 
Barrett’s esophagus and endobronchial cancer. Efficacy is high for small 
superficial tumors. 
This therapy is mainly used in dermatology to treat acne, rosacea, pustules, 
cutaneous tuberculosis and also it is used in fotorejuvenation. PDT is used in 
other medical areas like gastroenterology to treat pathologies of the 
gastrointestinal tract, neurology as coadjutant therapy of tumor surgery and in 
ophthalmology to treat neovascular membranes between others. (Arias et al. 
2007; NCI; Triesscheijn et al. 2006) 
 
2.4.3 How is it used? 
Cancer treatment based in PDT is initiated by injecting a photosensitizing agent 
into the bloodstream. PS is internalized by cells all over the body but its uptake 
and clearance time is higher in cancer cells than in normal cells. Exposure of the 
tumor to light is usually made approximately 24 to 72 hours after injection to 
allowing most of PS to left normal cells but remain in cancer cells. The PS in the 
tumor absorbs the light and produces an active form of oxygen that destroys 
nearby cancer cells.  
Each PS is activated by light of a specific wavelength and used to treat different 
areas of the body. This wavelength determines how far the light can travel into 
the body. The most ideal PS would be a chemically pure drug with preferential 
uptake in tumor, rapid clearance and a strong absorption peak at wavelengths 
greater than 630nm, corresponding to the red edge or infrared which is the most 
penetrating light. (Teixo 2013; Triesscheijn et al. 2006)  
Several photosensitizing agents are currently approved by the US Food and Drug 
Administration (FDA) to treat certain cancers, pre-cancers and other non-
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cancerous diseases. The use of one or another PS depends on the disease to 
treat and its localization. Those agents approved for clinical practice are shown in 
Table 3. 
 
Table 3. PS approved for clinical practice. (adapted from Allison and Sibata 2010; Teixo 
2013) 
PS group 
Commercial 
name 
Chemical name Clinical uses 
Porphyrin Photofrin®  
Photogem®  
Levulan®  
Metvix®  
Hexvix®  
Visudine®  
HpD  
HpD  
ALA  
M-ALA  
H-ALA  
Verteporfin  
Head and neck and brain 
tumors (HpD). 
Skin malignancies, actinic 
keratosis and superficial basal 
cell lesions, early and superficial 
non melanoma cutaneous 
malignancies, head and neck 
tumors, Barrett’s esophagus, 
bladder tumors and prostate 
cancer (ALA). 
Macular degeneration, 
ophthalmic astrocytoma, 
choroidal melanoma and 
various cutaneous malignancies 
(Veterporfin). 
Texaphyrin Lu-Tex; 
Antrin®  
Lutexaphyrin  Lung cancer metastasis and 
cutaneous metastasis for 
breast cancer. 
Chlorin Foscan®  
LS11; 
Photolon®  
LitxTM; 
ApoptesinTM  
Temoporfin  
Talaporfin  
HPPH  
Head and neck cancer, tumors 
of lip and oral cavity and 
esophageal cancer 
(Temoporfin). 
Recurrent tumors, refractory 
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Laserphyrin  
Photochlor  
liver metastasis and liver and 
recurrent head and neck 
cancers (Talaporfin). 
Esophageal cancer, Barrett’s 
esophagus and cutaneous 
lesions (HPPH). 
Phthalocianines 
 
Photosense®  
Pc4  
Phthalocyanine 
Phthalocyanine 
Infection, early stage and 
recurrent lip, pharynx, larynx 
and tongue lesions, primary 
lung, recurrent lung and 
esophageal tumors. 
Padoporfin  Tookad  Bacteriochlorophyll Prostate cancer. 
 
The light used for PDT can come from a laser or other sources like lamps and 
LEDs. Laser light can be directed through fiber optic cables to deliver light to 
areas inside the body. Light delivery for treatment of large surface areas such as 
treatment of skin diseases may also be effectively accomplished using 
fluorescent lamps, and for difficult anatomic areas with curvatures LED can be 
arranged in different geometric combination besides having a wide emission 
wavelength range and good power output. (Brancaleon and Moseley 2002; Mang 
2004) 
The main limitation of PDT is that the light needed to activate most PS cannot 
pass through more than about 1cm of tissue. For this reason, PDT is usually used 
to treat tumors on or just under the skin or on the lining of internal organs or 
cavities. PDT is also less effective in treating large tumors because the light 
cannot pass far into these tumors. PDT is a local treatment and generally cannot 
be used to treat cancer that has metastasized. 
PDT may also be repeated and may be used with other therapies, such 
as surgery, radiation, chemotherapy or HBOT. (Teixo 2013; Triesscheijn et al. 
2006) 
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2.4.4 Adverse effects and contraindications 
Some of the photosensitizers used in this therapy can make the skin and eyes 
sensitive to light for approximately 6 weeks after treatment. Thus, patients are 
advised to avoid direct sunlight and bright indoor light for at least 6 weeks. PS 
tends to build up in tumors and the activating light is focused on the tumor. As a 
result, damage to healthy tissue is minimal. However, PDT can cause burns, 
swelling, pain and scarring in nearby healthy tissue. Other side effects of PDT are 
related to the area that is treated and they can include coughing, trouble 
swallowing, stomach pain, painful breathing or shortness of breath; which are 
usually temporary. 
There are no long-term side effects if appropriate protocols are followed. (NCI; 
Triesscheijn et al. 2006) 
The main contraindication to PDT is porphyria, inherited or acquired disorders of 
certain enzymes, which can be caused by the persistence of some PS. Another 
contraindication is the coexistence of hepatic diseases or instable cardiac 
diseases. (Arias et al. 2007)    
 
2.4.5 Future perspectives 
Clinical trials and research studies are under way to evaluate the use of PDT for 
cancers of the brain, skin, prostate, cervix, intestines, stomach and liver. PDT is 
currently offered in only a few selected centers, although it is slowly gaining 
acceptance as an alternative to conventional cancer therapies. Other research is 
focused on the development of PSs that are more powerful, more specifically 
target cancer cells and are activated by light that can penetrate tissue and treat 
deep or large tumors as well on ways to improve equipment and the delivery of 
the activating light. (NCI; Triesscheijn et al. 2006) 
PDT is a noninvasive therapy that is consolidated to treat different cancers and 
other indications in diverse medical areas. The cost of the PSs is the first limit to 
the use of this treatment. Also, studies about the long term efficacy are required. 
(Arias et al. 2007)  
The combination of PDT with HBOT may enhance the efficacy of PDT improving 
the PS delivery. Getting a better efficacy allows the reduction of the quantity of 
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PS used in therapy and directly, can reduce the costs for this treatment and its 
secondary effects. 
Previous work developed by IBILI researchers with the PS BBr2HPC, evaluating 
its photodynamic action and cytotoxicity in the treatment of colorectal cancer, 
shown a good performance of the PS in PDT and had promising results in colon 
cancer treatment by demonstrating an increasing inhibition directly proportional 
to increasing PS concentration. Those cells were not able to recover, the damage 
was irreversible. (Laranjo 2014; Teixo 2013)  
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CHAPTER 3: MATERIALS 
AND METHODS 
In this section are defined the biological samples, chemicals, laboratory 
equipment and protocols used to see the outcome of the combination of HBOT 
and PDT and evaluate its effect with the MTT assay and the analysis of cell 
viability and cell cycle. As well, the software used to process the results of this 
alternative treatment is specified and complemented with the information 
provided in Chapter 1: Software that can be found in the Annexes of this 
project.  
 
3.1 Cells and culture conditions 
In this project, it has been studied a human cell line of colorectal 
adenocarcinoma, WiDr, obtained from the American Type Culture Collection  
(ATCC, CCL-218). The cell line was thawed and expanded in adherent culture 
according to supplier recommendations.  For all the studies, cells were kept at 
37°C in a humidified atmosphere with 95% air and 5% CO2 in an incubator 
(Binder C-50). Cells were cultured with Dulbecco's Modified Eagle's Medium 
(DMEM, Sigma D-5648) supplemented with 5% fetal bovine serum (Sigma 
F7524), 250μL of sodium pyruvate (Gibco 11360) and 1% of antibiotic 
(10.000units penicillin, 10mg streptomycin and 25μg amphotericin B per mL; 
Sigma A5955). 
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3.2 Combined therapy 
The combination of therapies has been studied in two ways, PDT after and before 
HBOT. The protocol used for each treatment is explained in 3.2.1 and 3.2.2. 
Culture plates of 24 wells have been used with 100.000cells/mL. All the plates 
have no treated control cells and cultured cells with solvent, and different 
concentrations of PS, in order to observe the effects induced by the PS in cell 
metabolic activity. Thus, 1 mg/mL concentration of the PS BBr2HPC is dissolved 
in a mixture of water (H2O), polyethylene glycol 400 (PEG400) and ethanol 
(EtOH) (50:30:20, v/v/v). The culture medium is changed before applying PDT 
to analyze only the effects induced by internalized PS. 
 
3.2.1 Hyperbaric oxygen therapy (HBOT) 
Cells are exposed to 100% oxygen (O2) pressurized to 1bar in an adapted 
hyperbaric chamber for the treatment of in vitro cells (Figure 6 (a)). The most 
wanted characteristic of the chamber is being able to maintain the pressure 
stable in the pan and it has been possible adjusting a pressure cooker (Silampos 
Lagos2) in two aspects: the tube of the oxygen tank was directly fitted with the 
adjustment valve of the pressure cooker and the other security valve was sealed. 
The pressure cooker has a maximum security pressure of 2,5bar, which allow us 
to perform our studies in perfect security conditions. The lid of the pressure 
cooker has a system that allow to maintain pressure constant and without loss. A 
decompressing valve was added. 
It has been established two different durations for the therapy; 30min and 
60min. During the treatment the chamber was placed in an incubator at 37ºC. 
This protocol has been improved based on consulted bibliography (Hjelde et al. 
2005; Chen et al. 2007; Bosco et al. 2013). The pressure of O2 is slowly raised 
until 1bar to compress the chamber and when the therapy is finished it must be 
decompressed using a proper valve. HBOT is performed 24h after incubation of 
PS, being performed before or after irradiation. 
 
 
                                                             
2 More characteristics about the pressure cooker Lagos from Silampos can be found on its website, which is the 
following: http://www.silampos.pt/fotos/editor2/manual_instrucoes_lagos.pdf.  
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3.2.2 Photodynamic therapy (PDT) 
The used photosensitizing agent is 5,15-bis(2-bromo-3-hidroxifenil)chlorin 
(BBr2HPC). Its maximum absorption is 627nm and it has been developed by 
IBILI researchers (Laranjo 2013; Serra, et al. 2010). A fluorescent light with a 
red filter (λcut-off<560nm) has been used as a source of irradiation (Figure 6 
(b)). Primarily, cells have been incubated with several concentrations of PS: 5, 
15, 25, 50, 100, 250 and 500nM. Irradiation is performed 24h after PS 
incubation by irradiating cells with a fluence of 7,5mW/cm2, until the delivery of 
a total energy of 10J. 
 
 
 (a)   (b)  
Figure 6. Equipment used for combined therapy. (a) Hyperbaric chamber used 
during the laboratory experience placed inside the incubator (b) PDT light source, 
fluorescent with red filter. (own source) 
 
3.3 Metabolic activity evaluation (MTT) 
Assays that measure metabolic activity are suitable for analyzing indirectly 
proliferation, viability and cytotoxicity and they are commonly used to monitor 
the response and viability of cells in culture after treatment with different stimuli. 
The proper choice of an assay depends on the number and type of cells used as 
well as the expected outcome. 
The MTT assay consists on the reduction of tetrazolium salts by metabolically 
active cells. Actively proliferating cells increase their metabolic activity while cells 
exposed to toxins will have decreased activity. It is a colorimetric assay for 
measure cell metabolic activity and indirectly can be used to assess cell viability.  
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The assay is performed with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide (thiazolyl blue or MTT), a water soluble salt when prepared in media or 
salt solutions acquires a yellowish color.  
Active mitochondrial dehydrogenases enzymes of living cells convert the 
dissolved MTT to an insoluble purple formazan by reducing the tetrazolium ring. 
Non metabolic active cells do not cause this conversion. 
For being able to measure the absorbance it is necessary to dissolve the crystals 
formed with a solution of HCl and isopropyl alcohol (2-propanol). (Dojindo; Teixo 
2013) In order to have the percentage of cellular proliferation, it is measured the 
absorbance of each cell media and its value is compared with a control solution 
by spectrophotometry. 
To perform this assay cells where previously treated with PDT and HBOT as 
described in 3.2 Combined therapy. This assay was performed 24h and 48h 
after the therapy. In total, 8 different conditions were subjected: PDT+HBOT 
30min, PDT+HBOT 60min, HBOT 30min+PDT and HBOT 60min+PDT; after 24h 
and 48h.  
 
Protocol 
To evaluate metabolic activity, the culture medium is discarded and each well of 
the culture plate is washed with 500μL of phosphate buffer saline (PBS), pH 7,4. 
After PBS is discarded and 200μL of MTT solution (0,5mg/mL; Sigma, EUA) are 
added in each well, it is incubated for 2h in an incubator at 37°C in the dark, as 
MTT is sensible to light. After the incubation, crystals of formazan (Figure 7) are 
dissolved with 200μL of a 0,04M solution of hydrochloric acid in isopropanol in 
constant agitation for 30min. When crystals are dissolved, content of each well is 
transferred to a 96 wells plate in order to measure its absorbance with a 
spectrometer in the wave length of 570nm and 620nm. The program Gen5 1.09 
allows the measurement and display of the absorbance made with the 
spectrometer, which is connected to the computer. 
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Figure 7.  MTT molecule (C18H16BrN5S) reduction forming MTT formazan (adapted from 
Dojindo). 
The results are given in percentage of inhibition of cell proliferation produced by 
the treatment normalized to 100% as expressed in equation 1. 
      (1) 
Those percentages allow determining the concentration of PS that inhibits the 
metabolic activity in a 50% (EC50) and the fitting of the results with a sigmoid 
function to evaluate the changes on the number of metabolic active cells with a 
rising PS concentration (R2). Those values are obtained with the software 
OriginPro 8.  
3.4 Flow cytometry 
The flow cytometry is a laser-based technology that simultaneously measures 
and then analyzes multiple physical characteristics of single particles, usually 
cells, as they flow in a fluid stream through a beam of light. This technique is 
used for cell counting, cell sorting, biomarker detection and protein engineering. 
Any suspended particle or cell from 0.2–150μm in size is suitable for analysis. 
Cells from solid tissue must be disaggregated before analysis. 
It makes possible to determinate the intracellular mechanisms that lead to the 
inhibition of cellular proliferation. The evaluation of cellular viability to 
determinate the type of cell death can be achieved by the double stand with 
annexin V-FITC (AnV-FITC) and propidium iodide (PI). The evaluation of the 
cellular cycle to see its alterations is possible by evaluating content in DNA by 
labeling cells with PI. (Teixo 2013) 
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Figure 8. Groups of 
cellular viability. 
Healthy, apoptotic 
and/or necrotic cells 
detection with markers. 
(adapted from BD 
Biosciences) 
Protocol 
Three different conditions have been analyzed to study cellular effects of HBOT, 
PDT and PDT+HBOT 60min compared to none treated colon cancer cells. The PS 
concentration used with PDT is 58,5nM as justified in previous work. (Laranjo 
2014) Culture flasks with a growth area of 25cm2 have been used to apply he 
correspondent therapy with 3 million cells. The culture medium is changed before 
incubation with PS. After 24h, before therapy, the 
culture medium is changed and cells are washed with 
PBS before the new medium is added to remove the 
excess of PS. 
3.4.1 Analysis of cellular viability 
Apoptosis is a normal genetically programmed process 
that occurs during embryonic development and in the 
maintenance of tissue homeostasis, under pathological 
conditions and in aging, where a cell actively 
participates in its own destructive processes. In 
apoptotic cells, the phospholipid phosphatidylserine 
membrane is translocated from the inner to the outer 
leaflet of the plasma membrane, thereby exposing it 
to the external cellular environment.  
AnV-FITC is a protein with high affinity for 
phosphatidylserine and binds to its exposed apoptotic 
cell surface. That translocation precedes the loss of 
membrane integrity, which accompanies the later 
stages of cell death resulting from either apoptotic or 
necrotic processes.  
AnV-FITC is typically used in conjunction with a vital 
dye such as PI for identification of early and late 
apoptotic cells and necrotic cells. The membranes of 
cells undergoing late apoptosis or necrosis are 
permeable to PI. This process is summarized in Figure 
8.
Photodynamic therapy improvement with hyperbaric oxygen therapy for human colon cancer treatment 
-42-
The application of this double labeling with AnV-FITC and PI allows the following 
classification of cell population depending on its response: (BD Biosciences; Teixo 
2013) 
 Group I: viable cells or no measurable cell death, negative result for both
markers.
 Group II: cells in early apoptosis with intact membranes, positive result
for AnV-FITC and negative result for PI.
 Group III: cells in late apoptosis or necrosis, positive result for both
markers.
 Group IV: cells in necrosis, positive result for PI and negative result for
AnV-FITC.
Protocol 
Cells obtained after trypsinization are placed in cytometry tubes and centrifuged 
again at 2500rpm. The supernatant is decanted and the resultant pellet is 
suspended in 100μL of a ligation buffer (1x). It is incubated 15min in dark at 
ambient temperature after the addition of 2,5μL of AnV-FITC and 1μL of PI (KIT 
Immunotech, Beckman Coulter, Check Republic) homogenized in a vortex. 
Subsequent to the incubation it is added 400μL of ligation buffer (1x) and it is 
analyzed in the cytometer using the wave lengths of 525nm for AnV-FITC and 
640nm for PI.  
The results of this technique are presented in percentage of cells from each 
group.  
3.4.2 Analysis of cell cycle 
This analysis allows determining the cell cycle status or tissue localization of 
individual cells within proliferating populations by using DNA dyes, as propidium 
iodide (PI), to verify the existence of alterations produced during the therapy 
given to the cells with HBOT and PDT. 
The cell cycle consists in a sequence of events where one cell duplicates its 
genetic material and divides into two daughter cells that are genetically identical. 
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Cell growth, replication and division in eukaryotic cells occur according to a 
highly controlled series of events called cell cycle. The cell cycle is shown in 
Figure 9 and it has four main phases and: (BD Biosciences; Teixo 2013) 
 
 During the first stage, G1, cells synthesize RNA and proteins to induce 
growth when the requisite signals of their environment are received. 
Corresponds to the first stage of the interphase. 
 When there are proper conditions to cells can divide, cells enter the S 
stage of cell cycle and start DNA synthesis and replicate their 
chromosomal DNA. This phase belongs to the interphase. 
 In the G2 phase, cells continue to grow and prepare for mitosis. Is the last 
stage of the interphase. 
 Mitotic phase, M, the mother cell divides into two genetically identical 
daughter cells.  
 
 
 
Figure 9. Cell cycle phases. (BD Biosciences) 
 
Protocol 
Cells obtained after trypsinization are placed in cytometry tubes and centrifuged 
again during 5min at 1000rpm. The supernatant is decanted and it is incubated 
30min in dark at 4°C after the addition of 200μL of ethanol 70% with the tube in 
agitation on the vortex. After the incubation 2mL of PBS (1x) is added and 
centrifuged at 2500rpm during 5min. The supernatant is decanted again and it is 
added 200μL of PI (PI/RNase Solution), homogenized in the vortex and incubated 
Photodynamic therapy improvement with hyperbaric oxygen therapy for human colon cancer treatment 
-44- 
15min in dark at ambient temperature. Finally it is homogenized again and 
analyzed in the cytometer using the wave lengths of 488nm for PI. 
The results of this technique are presented in percentage of cells from each 
phase of the cell cycle. 
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CHAPTER 4: 
RESULTS 
The results presented in this chapter were obtained for the metabolic activity 
evaluation and the two analyses of flow cytometry, cellular viability and cell 
cycle. All the experiments were performed in Biophysics Unit, Faculty of 
Medicine, University of Coimbra in collaboration with Ricardo Teixo and Ana 
Margarida Abrantes under supervision of Professor Maria Filomena Botelho. 
 
4.1 Metabolic activity evaluation (MTT) 
In order to evaluate the improvement of the photodynamic potential of PDT and 
HBOT therapies in different conditions, the assay of cytotoxicity was performed. 
With it, the level of metabolic activity can be analyzed in the colorectal cancer 
cell line (WiDr) after performing the different treatments approaches studied. 
In order to obtain the EC50 and R
2, the average and the standard deviation (SD) 
of the percentages of metabolic activity obtained by MTT assay, after the 
combined therapy, are calculated for 24h and 48h for each condition. Those 
values are shown in Table 5 and Table 6, which can be found in the Chapter 2: 
Detailed results of the Annexes, and they allow obtaining the curve of dose-
response which is displayed in Figure 10 fitted with a sigmoid model. The final 
results for the values of EC50 and R
2 are shown in Table 4. 
 
Olga Ciutad Castejón 
-47- 
 
(a) 
 
(b) 
 
(c) 
 
(d) 
Figure 10. Curve dose-response obtained by MTT assay displayed 24 and 48 hours 
after the therapies for all conditions (a)PDT + HBOT 30min (b)PDT + HBOT 60min 
(c)HBOT 30min + PDT (d)HBOT 60min + PDT. 
 
It can be verified that preliminary results shown values of EC50 for 24h after the 
treatments are very similar between all the treatments. The values for the 
treatments of PDT+HBOT 30min, PDT+HBOT 60min, HBOT 30min+PDT and 
HBOT 60min+PDT were 17,96nM, 18,43nM, 18,26nM and 19,65nM respectively. 
Between the values at 48h there is a tendency for a lower EC50 value for the 
treatment HBOT 60min+PDT. The EC50 obtained for the treatments PDT+HBOT 
30min, PDT+HBOT 60min, HBOT 30min+PDT and HBOT 60min+PDT were 
17,10nM, 15,98nM, 18,39nM and 7,76nM. However, it could be observed R2 
values lower than 0,90 showing that further studies are needed. 
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Table 4. EC50 and R
2 calculated with the values of Table 1 and 2 in ‘Chapter 2: Detailed 
results of the Annexes’ with the program OriginPro 8, for each condition after 24h and 
48h of the corresponding treatment. (own source) 
MTT Treatment EC50 (nM) R
2 
24h  
PDT+HBOT 30min 17,95689 0,87295 
PDT+HBOT 60min 18,42253 0,88356 
HBOT 30min+PDT 18,2516 0,87703 
HBOT 60min+PDT 19,64873 0,89535 
48h 
PDT+HBOT 30min 17,0464 0,72418 
PDT+HBOT 60min 15,97038 0,56977 
HBOT 30min+PDT 18,38926 0,49718 
HBOT 60min+PDT 7,75226 0,32573 
 
4.2 Flow cytometry studies 
After verifying the influence of the combined therapies on the level of metabolic 
activity, it is needed to evaluate the type of cell death and the effects induced on 
the cell DNA after therapies. 
The results obtained in the flow cytometry studies are shown for the four 
different conditions studied. For both cell viability and cell death as well for cell 
cycle studies, results are expressed as the mean percentage of cells with 
standard deviation also represented. The final results are available in Tables 7 
and 8, which can be found in the Chapter 2: Detailed results of the Annexes.   
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4.2.1 Cellular viability 
 
Figure 11. Results of cellular viability assay. Type of cell death 24h after the treatment 
for each condition in WiDr cell line. Graphics obtained by the software GraphPad Prism. 
 
The cellular viability and type of cell death percentages are presented in Figure 
11 obtained by double labeling with AnV-FITC and PI. 
The number of viable cells maintains practically the same in control cells and 
HBOT, 70% and 61,67% respectively, but decreases with PDT and it is even 
more notable in the combination of PDT+HBOT 60min, 32,33% and 19% of 
viable cells. The percentage of cells in initial apoptosis does not present 
alterations with treatments when compared to control cells, being all the values 
between 9% and 15,33%. The same tendency of results is observed for cell 
death by late apoptosis/necrosis, being observed a slight increase from 4,67% to 
12% of the HBOT alone treatment and PDT+HBOT 60min respectively. However, 
our preliminary results appear to present a tendency for an increase in cell death 
by necrosis. The percentage of cells in necrosis in control conditions is of 
11,67%, and the application of therapies presents a tendency to an increase to 
18,33% for HBOT alone, 45% for PDT and 60% for the combined therapy, in the 
combination of PDT followed by 60min of HBOT.  
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4.2.2 Cell cycle 
 
Figure 12. Results of cell cycle analysis. Phases of the cell cycle 24h after the treatment 
for each condition in WiDr cell line. Graphics obtained by the software GraphPad Prism. 
(own source) 
 
In Figure 12 are displayed the results, in percentage, of the analysis with PI for 
each phase of the cell cycle.  
The control cell culture without treatment does not have any percentage for the 
phase Pre-G0, when the others therapies show a percentage value between 
1,89% and 6%. The therapies have not induced significant differences in the 
number of cells in the stages of G0/G1, S and G2/M. The percentages of HBOT 
has a more similar structure with the control, the percentage of cells in the stage 
S is bigger than cells in G2/M stage. On the other hand, PDT and PDT+HBOT 
60min have bigger percentages of cells in the stage G2/M than S.  
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CHAPTER 5: 
DISCUSSION 
In order to evaluate the metabolic activity of the colon cancer cells after the 
combined therapies, MTT assay was performed to obtain EC50 values, value 
commonly used to quantify the therapeutic effect of a therapy with drug (Laranjo 
2014), and R2, to have a reliability indication.  
The values of EC50 24h and 48h after the treatments have a tendency to not 
shown any significant differences between. Treatment based on HBOT for 60min 
followed by PDT presents lower value at 48h after the treatment. Nevertheless, 
R2 values do not reach 0,90 and just for the metabolic activity assay after 24h 
the values get close to 0,90, indicating that further studies are needed. Those 
values are shown in Table 4. 
The treatment with a smaller EC50 has clinical and economical advantages, as 
discussed earlier in this project, which are reduced adverse effects and low cost 
of the PS by reducing the quantity of PS used. Following this logic, the best 
treatment to consider should be HBO 60min+PDT, with an EC50 of 7,76nM. 
However and as previously described, R2 should be considered before this 
analysis.  
Comparing those results with the ones obtained in Laranjo 2014 where PDT alone 
has been studied with the PS BBr2HPC in the human colorectal adenocarcinoma 
cell line WiDr, all the combinations of therapies had shown a lower EC50 value 
than just the application of the photodynamic treatment with BBr2HPC 
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photosensitizing agent, as in the present study. The EC50 for carcinoma colorectal 
after PDT treatment was 58,5nM for 24h after the treatment. (Laranjo 2014) 
As the values of EC50 maintain practically the same during the time after 
incubation considered (24h and 48h), we can assume that the combination of 
PDT and HBOT would cause irreversible damage in cells and thus, that there is 
no capacity of recovery after the alterations produced by the different 
treatments. 
By using MTT assay we also verify that combination of PDT and HBOT induce a 
response dose-dependent, as increasing concentrations of PS induced increasing 
inhibition of metabolic activity in WiDr cell line, as is shown in Figure 10. 
The metabolic activity assay can give some indication about the proliferative 
capacity of cells after the treatment but it does not show information about the 
intracellular mechanisms that leads to its cytotoxicity. For that reason it was 
used flow cytometry techniques, namely the double labeling with AnV-FITC and 
PI to assess the type of cell death induced by the treatments evaluated in this 
project, as well as the DNA marker PI to identify alterations in the cellular cycle.  
Flow cytometry studies were performed 24h after each therapy alone in order to 
determine its cell effects compared to normal WiDr cells and for the treatment 
PDT+HBOT 60min. As time has not permitted start this second phase after 
having the complete results of metabolic activity, PDT+HBOT 60min was the best 
combined therapy at that point with an EC50=10,12 and R
2=0,99. 
It is important to determine if the cytotoxicity is produced by the mechanism of 
necrosis or apoptosis. Necrosis is detected for the loss of integrity of the 
cytoplasmatic membrane and its capacity of excluding PI and apoptosis for the 
high affinity of the protein AnV-FITC with phosphatidylserine of the membrane. 
The number of viable cells is considerably reduced in treatments where PDT is 
involved; however, the treatment with HBOT has a percentage of viable cells 
similar to the control, it just varies an 8,33%. That can be evidence about the 
non effect of HBOT as a stand-alone therapy. It has been observed that the 
percentage of cells in initial apoptosis and late apoptosis/necrosis remains 
without differences compared to control cells. The number of cells in late 
apoptosis/necrosis is slightly higher in the therapies with photodynamic therapy 
involved, PDT and PDT+HBOT 60min, but it does not imply any notable result. 
Nevertheless, it has been detected a tendency for an increment of cell death by 
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necrosis in PDT compared with the control and that difference is even bigger in 
the condition of PDT+HBOT 60min representing a 45%, 11,67% and 60% 
respectively.  
Apoptosis is frequently called programmed cell death and proximately 10 million 
cells per day undergo apoptosis in a healthy adult human due to alterations. 
Such mechanism is needed to preserve the homeostasis of the organism and to 
control tissue size among others. The process of necrosis refers to a gain in cell 
volume, swelling of organelles, plasma membrane rupture and subsequent loss 
of intracellular contents; considered an accidental and uncontrolled, non-
programmed form of cell death whereby dramatic changes in crucial cell 
parameters of metabolism and cell structure take place, generally caused by 
chemical or physical injury. The consequences of necrotic and apoptotic cell 
death are quite different. In the case of necrosis, the inflammatory response may 
be caused by cytosolic constituents pouring into the intercellular space through 
the damaged plasma membrane; in apoptosis these products are safely isolated 
inside macrophages. Accumulating evidence shows that necrotic cell death is 
sometimes also controlled and programmed when a cell is unable to die by 
apoptosis. (Chaabane et al. 2013) An apoptotic response should be preferable in 
front of the necrotic response of colorectal cancer cells to the PDT and 
PDT+HBOT 60min treatment.  
During the Pre-G0 phase the cell is not dividing. In G0/G1 cells produce RNA and 
synthesize protein and in the next phase, S, the DNA is duplicated. In the last 
stage, G2/M, cells grow and divide into two similar cell daughters. The obtained 
results do not show variance between the percentages of cells in each phase of 
the cell cycle.  In spite of that, little differences can be noticed. The control does 
not have cells in the phase Pre-G0 and the other therapies do. The control and 
HBOT cells have a similar cell behavior, as PDT and PDT+HBOT 60min do. The 
first group has lower values in the stages G0/G1 and S and higher values in the 
phases Pre-G0 and G2/M than the second group, the therapies with 
photodynamic irradiation. It can indicate that treatments implying irradiation 
does not allow the cell duplication. 
In this project, it has been determinate the therapy PDT+HBOT 30minutes the 
best treatment for colorectal adenocarcinoma with an EC50=17,96nM and 
R2=0,87 with an improvement compared to the treatment just with PDT, which 
had an EC50=58,50nM. (Laranjo 2014) This treatment showed no capacity of 
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recovery after the alterations produced. The most percentage of cell death 
belongs to the process of necrosis and this therapy seems to not allow the cell 
duplication. 
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CHAPTER 6: 
CONCLUSION 
Photodynamic therapy (PDT) has been accepted as an alternative treatment for 
cancer, especially for solid tumors like carcinomas. It has some advantages over 
the current cancer chemotherapy and radiation therapy in terms of less adverse 
effects and targeted delivery. PDT requires three elements: light, a 
photosensitizer and molecular oxygen; (Shao et al. 2012) and is able to induce 
cell death by oxidative stress trough activation with light of a non-toxic 
photosensitizer. (Teixo 2013; Triesscheijn et al. 2006) The efficacy of PDT can be 
diminished because of regions of hypoxia, areas with a poorer oxygenation also 
present in colorectal cancer, suggested as an adverse prognostic factor for 
patient outcome. (Sudhakar et al. 2013; Vaupel and Mayer 2007) To alter the 
hypoxic state and improve treatment outcome it is used the hyperbaric oxygen 
therapy (HBOT). (Daruwalla and Christophi 2006; Ogawa et al. 2013) 
Four possible treatments have been studied to improve PDT outcome in WiDr cell 
line: PDT+HBO 30min, PDT+HBO 60min, HBO 30min+PDT and HBO 60min+PDT. 
For PDT it has been used the photosensitizing agent BBr2HPC and irradiation 
with 10J, and for HBOT it has been applied, 1bar of 100% O2. To study their 
outcome, metabolic activity assay with MTT have been performed 24h and 48h 
after the treatment revealing an improvement from EC50=58,50nM of PDT 
treatment alone (Laranjo 2014) to EC50=17,96nM of PDT+HBOT 60min, both 
assays 24h after the therapy. The value of R2 does not reach 0,90 and more 
assays should be realized to have a better value for the fitting results and a 
Olga Ciutad Castejón 
-57- 
definitive decision about the best therapy, as the results for all the therapies 
analyzed 24h after the treatment are similar.  
To analyze the cytotoxicity effects of the treatment, two flow cytometry analysis 
have been performed: cellular viability assay and cell cycle analysis. To compare 
the effects of the different therapies, 24h after the treatment four conditions 
have been subjected to study: control, PDT, HBOT and PDT+HBOT 60min. As 
mentioned before, the combined therapy analyzed should had been the best of 
the eight studied before, PDT+HBOT 30min 24h after the treatment. To confirm 
the cellular effects of the colorectal cancer therapy, both assays of flow 
cytometry should be repeated studying the therapy with better EC50 and R
2. The 
cellular viability assay showed an increased percentage of necrotic cells, although 
that should be preferable apoptosis. In regard to cell cycle analysis, it has not 
shown differences but it can indicate not allow the cell duplication or in other 
words, the therapy does not allow colorectal cancer cell proliferate.  
In order to assure the therapy conditions and effects, other assays can be 
performed in order to complement the analysis realized. Those assays could be 
Alamar blue to complement the metabolic activity results and assays to evaluate 
the therapy cytotoxicity such as comet assay and p53 protein expression. 
When this first phase, in vitro studies, is completed a second phase of in vivo 
studies should be develop by making an orthotopic animal model of colorectal 
adenocarcinoma and evaluate the different therapeutics approaches in the 
orthotopic model. Finally, ex vivo studies by excising the tumors of the animal 
model and perform histological analysis and immunohistochemical studies and 
analyze the expression of VEGF and HIF-1 by western blot.  
This project has highlighting the combined therapy hyperbaric photodynamic 
therapy as a promising therapeutic approach for adenocarcinoma colorectal 
cancer. 
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CHAPTER 1: 
SOFTWARE 
In this chapter are shown the different informatics programs used to obtain and 
evaluate the results with MTT. 
 
1.1 Gen5 1.09 
This software is used to obtain the values of absorbance in the wave length of 
570nm and 620nm. The interface and the followed steps to acquire the results 
are shown bellow. Before starting with the absorbance readings, it must be 
assured that the spectrometer is connected and turned on. The plate has to be 
introduced without the cover. The process followed is shown in Figures 13-20.  
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Figure 13. Step 1 with Gen5. ‘Experiment’ is selected to open a new file. (own 
source) 
 
 
Figure 14. Step 2 with Gen5.The kind of protocol of the new file is defined for MTT 
selecting ‘MTT Hugo.prt’. (own source) 
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Figure 15. Step 3 with Gen5. ‘Read plate’ is available with the button rounded in red. 
It will open the spectrometer tray allowing the reading of the plate. (own source) 
 
 
Figure 16. Step 4 with Gen5. This window is shown when ‘Read plate’ is clicked and 
by selecting ‘Read’ it will permit the saving of the experiment. (own source) 
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Figure 17. Step 5 with Gen5. To continue, the experiment must be saved. (own 
source) 
 
 
Figure 18. Step 6 with Gen5. The temperature is displayed on the screen to validate 
the experiment. Before the next steps, the plate must be in the tray. (own source) 
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Figure 19. Step 7 with Gen5. The spectrometer reads first the 570nm and when it is 
finished, the results are presented on the screen. By selecting the Excel icon, rounded in 
red, the results are exported to an Excel sheet.  To visualize the 620nm results, ‘Data’ 
must be changed to ‘620’, rounded in blue. (own source) 
 
 
Figure 20. Step 8 with Gen5. When 620nm results are ready they appear on the 
screen and are exported in the same way as the 570nm results. They appear in the same 
Excel sheet. (own source) 
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1.2 OriginPro 8 
This program allows determining the EC50 and the R
2 by the percentages 
obtained by metabolic activity evaluation. The calculation of the concentration 
logarithm with base 10, the average of the percentages and the standard 
deviation (SD) of the group of results of MTT for each condition is needed to 
obtain the values of EC50 and R
2. Those previous values are obtained with Excel 
as it is explained in the 3.3 MTT assay section of the Technical Report. The 
process followed is shown in Figures 21-25. 
 
 
Figure 21. Step 1 with OriginPro 8. The X axe corresponds with the concentration 
logarithm with base 10, the average of the percentages corresponds with Y axe and the 
SD is set as Y error. (own source) 
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Figure 22. Step 2 with OriginPro 8. The values on the table are selected and a fit 
sigmoidal analysis is chosen as the image shows. (own source) 
 
 
Figure 23. Step 3 with OriginPro 8. In ‘Function Selection’ a dose-response 
‘DoseResp’ is selected as ‘Function’ and in the ‘Parameters’ section the top and bottom 
values of Y axe are set to 100 and 0 respectively. (own source) 
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Figure 24. Step 4 with OriginPro 8. A set of numeric values are displayed and among 
them the value of ‘EC50’ and ‘Adj. R-Square’ (R
2) as marked in the image. (own source) 
 
 
Figure 25. Step 5 with OriginPro 8. The dose response curve is obtained too with the 
tables shown on Figure 24. (own source) 
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CHAPTER 2: DETAILED 
RESULTS 
The percentages obtained by the spectrometer for each concentration and 
condition are shown in Table 5 and Table 6 for 24h and 48h respectively. 
In Table 7 and Table 8 it is available the average and the SD for cellular 
viability and cell cycle assay. 
 
Table 5. PS concentration logarithm with base 10, average and standard deviation 
for MTT assay displayed 24 hours after the therapies. 
MTT 24h 
Treatment PS concentration log10 [nM] Average SD 
P
D
T
+
H
B
O
 3
0
m
in
 
0nM - 100,00 0 
5nM 0,69897 90,77 7,276597 
15nM 1,176091 79,14 8,257605 
25nM 1,39794 8,29 1,577846 
50nM 1,69897 2,50 1,274408 
100nM 2 2,49 1,684832 
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250nM 2,39794 1,50 0,427801 
500nM 2,69897 1,74 0,651415 
P
D
T
+
H
B
O
 6
0
m
in
 
0nM - 100,00 0 
5nM 0,69897 87,01 14,40092 
15nM 1,176091 81,62 7,868636 
25nM 1,39794 10,13 2,690935 
50nM 1,69897 3,15 1,686697 
100nM 2 3,22 1,557 
250nM 2,39794 2,32 1,198665 
500nM 2,69897 2,29 1,992306 
H
B
O
 3
0
m
in
+
P
D
T
 
0nM - 100,00 0 
5nM 0,69897 93,71 12,35839 
15nM 1,176091 76,84 9,121323 
25nM 1,39794 16,89 3,683127 
50nM 1,69897 2,54 1,291917 
100nM 2 3,81 1,706028 
250nM 2,39794 2,39 1,339341 
500nM 2,69897 1,37 0,707513 
H
B
O
 6
0
m
in
+
P
D
T
 
0nM - 100,00 0 
5nM 0,69897 92,51 9,168735 
15nM 1,176091 80,44 10,83044 
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25nM 1,39794 23,82 5,886127 
50nM 1,69897 1,39 1,010564 
100nM 2 1,02 0,712065 
250nM 2,39794 1,12 0,408848 
500nM 2,69897 1,10 0,513025 
 
Table 6. PS concentration logarithm with base 10, average and standard deviation 
for MTT assay displayed 48 hours after the therapies. 
MTT 48h 
Treatment PS concentration log10 [nM] Average SD 
P
D
T
+
H
B
O
 3
0
m
in
 
0nM - 100,00 0 
5nM 0,69897 86,41 9,76482 
15nM 1,176091 75,69 13,84828 
25nM 1,39794 3,38 1,421691 
50nM 1,69897 1,65 0,744645 
100nM 2 1,24 0,615866 
250nM 2,39794 1,63 0,569096 
500nM 2,69897 1,43 0,623476 
P
D
T
+
H
B
O
 6
0
m
in
 0nM - 100,00 0 
5nM 0,69897 84,51 10,61137 
15nM 1,176091 63,23 11,37707 
25nM 1,39794 2,45 0,680837 
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50nM 1,69897 1,15 0,338846 
100nM 2 1,37 0,626203 
250nM 2,39794 1,16 0,378903 
500nM 2,69897 1,18 0,475672 
H
B
O
 3
0
m
in
+
P
D
T
 
0nM - 100,00 0 
5nM 0,69897 91,34 12,19225 
15nM 1,176091 91,34 11,80886 
25nM 1,39794 2,88 0,628228 
50nM 1,69897 1,56 0,469441 
100nM 2 1,31 0,327988 
250nM 2,39794 1,17 0,32344 
500nM 2,69897 1,36 0,44897 
H
B
O
 6
0
m
in
+
P
D
T
 
0nM - 100,00 0 
5nM 0,69897 78,74 4,504809 
15nM 1,176091 75,24 3,972903 
25nM 1,39794 3,10 1,007279 
50nM 1,69897 1,51 0,407247 
100nM 2 0,84 0,113968 
250nM 2,39794 0,80 0,058223 
500nM 2,69897 1,21 0,438694 
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Table 7. Results for cell cycle assay 24h after the treatment. Average and 
standard deviation for each type of cell death, viable, initial apoptosis, late 
apoptosis/necrosis and necrosis. 
Treatment 
Viable 
Initial 
Apoptosis 
Late 
Apoptosis/Necrosis 
Necrosis 
Average SD Average SD Average SD Average SD 
Control 70 5,20 11,67 2,52 6,67 5,03 11,67 0,58 
PDT 32,33 10,69 11,67 1,53 11 9,54 45 1 
HBO 
60min 
61,67 8,39 15,33 5,86 4,67 1,53 18,33 4,16 
PDT+HBO 
60min 
19 5,29 9 1 12 3 60 5 
 
Table 8. Results for cell cycle assay 24h after the treatment. Average and 
standard deviation for each cell cycle phase, Pre-G0, G0/G1, S and G2/M. 
Treatment 
Pre-G0 G0/G1 S G2/M 
Average SD Average SD Average SD Average SD 
Control 0 0 57,80 1,64 26,40 1,52 15,80 2,95 
PDT 5,40 3,21 55,20 9,20 21,40 6,80 23,40 4,51 
HBO 60min 1,86 0,69 59 6,27 23,14 4,81 18,29 2,63 
PDT+HBO 
60min 
6 2,45 53 7,44 19,50 8,50 27,50 5,74 
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CHAPTER 1: 
BUDGET 
This budget details the costs of the elaboration of this project. Note that the 
most expensive concept in the budget is personnel costs, due to the 
reusable laboratory equipment during several years. 
 
1.1 Materials budget 
The materials budget is divided in laboratory equipment, computer and 
software and office costs shown in Tables 9-12. Those costs are calculated 
for the period of time that one academic semester last, corresponding to a 
total of 16 weeks of work. 
Other laboratory equipment used in the current research but acquired years 
ago, like Binder incubator, vertical laminar flow cabinet (Holten Laminair 
HB2448), PDT fluorescent and red filter, centrifuge 40mL, vortex, flux 
cytometer, spectrometer (Biotek Synergy HT multi-mode microplate reader) 
and Vacusafe comfort aspiration system, and other laboratory material, as 
pipette P20, pipette P10, repetitive pipette, pipette 3mL and test tubes 
rack, allows a saving in the project budget of almost 26.000€. 
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Table 9. Laboratory costs. 
Concept 
Fixed 
cost 
(€/unit) 
Number 
of units 
Total (€) 
Laboratory equipment 2.047,75 € 
Pressure cooker (Silampos Lagos) 69,90 1 69,90 
O2 tank 680L  1.962,90 1 1.962,90 
Security valve 14,95 1 14,95 
Biological and chemical material 1.687,35 € 
WiDr cell line 575 1 575 
Dulbecco's Modified Eagle's Medium 
(DMEM, Sigma D-5648) 10L 
30,20 1 30,20 
Fetal bovine serum (Sigma F7524) 50mL 20,38 1 20,38 
Sodium pyruvate (Gibco 11360) 100mL 11,50 1 11,50 
Antibiotic Antimycotic Solution (100×), 
Stabilized (Sigma A5955) 20mL 
15,20 1 15,20 
Phosphate buffer saline 200mL (PBS) 77,50 1 77,50 
Polyethylene glycol 400 (PEG400) 1L 17,12 1 17,12 
Ethanol (EtOH) 475mL 11,65 1 11,65 
Thiazolyl blue or MTT 500mg 45,60 1 45,60 
Hydrochloric acid (HCl) 100mL 36,70 1 36,70 
Isopropyl alcohol (2-propanol) 100L 34,40 1 34,40 
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Buffer solution (1x) 1L 19,77 1 19,77 
Annexin V-FITC Apoptosis Detection Kit (100 
tests) 
490 1 490 
Ethanol 70% 500mL 7,33 1 7,33 
Cell Cycle Assay Kit (100 tests) 295 1 295 
Laboratory material 984,73 €  
Latex gloves (50 pairs) 18,20 4 72,8 
Sterile 24 well plate (100 units) 103 1 103 
Sterile 96 well plate (100 units) 99 1 99 
Sterile culture flasks 25cm2 (200 units) 89 1 89 
Test tubes (200 units) 57,40 1 57,40 
Pipette tips 0,5-20 μL (96 units) 132 1 132 
Pipette tips  0,1-10 μL (96 units) 132 1 132 
Precision Dispenser Tips 10mL (100 units) 128,90 1 128,90 
Eppendorf tube 5mL (50 units) 43,20 1 43,20 
Centrifuge tubes 50mL (100 units) 72,50 1 72,50 
Parafilm (4in. × 125ft) 37,10 1 37,10 
Wash bottle screw caps 1,49 1 1,49 
Cellulose bobbin (2 rolls) 16,34 1 16,34 
  Gross total 4.719,83 
  IVA (21%) 991,17 
  Total 5.711 
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Table 10. Computer and software costs. 
Concept 
Fixed cost 
(€/unit) 
Number of 
units 
Total (€) 
Gen5 1.09 (undefined) 2.510,57 1 2.510,57 
OriginPro 8 (1 year license) 1.168,71 1 1.168,71 
Acer Laptop ES1-512-P6EL 329,99 1 329,99 
Microsoft Office 365 (1 year 
license) 
69,99 1 69,99 
  Gross total 4.079,26 
  IVA (21%) 856,64 
  Total 4.935,90 
 
Table 11. Office costs. 
Concept Cost (€/month) Months Total (€) 
Electricity bill 100 5 500 
  Gross total 500 
  IVA (21%) 105 
  Total 605 
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1.2 Personnel budget 
The costs are calculated for the period of time that the investigation project 
lasted, 5 months. The total cost is shown in Table 12. 
 
Table 12. Personnel costs. 
Concept Cost (€/h) Hours Total (€) 
Student 10 800 8.000 
Supervisor  18 900 16.200 
Project director 30 1.000 30.000 
  Gross total 54.200 
  IVA (21%) 11.382 
  Total 65.582 
 
  
Olga Ciutad Castejón 
-85- 
1.3 Global budget 
 
Table 13. Total cost of the project, IVA included. 
Concept Total (€) 
Laboratory costs 5.711 
Computer and software costs 4.935,90 
Office costs 605 
Personnel costs 65.582 
Total 76.833,90 
 
The total cost of the project is 76.833,90€ as it is indicated in Table 13. 
 
 
